Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion’s 100% US subsidiary, Celltrion USA, Inc., has decided to acquire a 100% equity stake in Imclone Systems LLC from Eli Lilly Group for approx. KRW 460.0B (USD 330M) to establish a local US API manufacturing base.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Decision on Acquisition of Shares and Equity Securities of Other Corporation (Voluntary Disclosure – Major Management Matters of Subsidiary)
- Acquiring Subsidiary: Celltrion USA, Inc. (CEO: Bon-Joong Kim, Main Business: Pharmaceutical Wholesale & Retail)
- Target Entity: Imclone Systems LLC (US-based pharmaceutical manufacturing LLC)
- Counterparty: Imclone Systems Holdings, Inc. (Subsidiary of Eli Lilly and Company / Eli Lilly co-signed as guarantor)
- Acquisition Details & Amount:
- Acquisition Amount: KRW 460,020,000,000 (approx. KRW 460.0B / USD 330,000,000)
- Applied Exchange Rate: Initial basic exchange rate on September 23, 2025 (USD/KRW 1,394.00)
- Acquisition-to-Assets Ratio: 2.18% (Based on Celltrion’s FY2024 consolidated total assets of KRW 21,055,222,437,706)
- Post-Acquisition Ownership: 100% (Cash acquisition)
- Purpose of Acquisition: Establishing a local API manufacturing system in the US
- Expected Acquisition Date: Pending as of filing date (To be updated upon confirmation following regulatory procedures)
- Board Resolution Date (CEO Approval Date at Subsidiary): September 20, 2025
- Summary Financial Position of Target (Adjusted Basis / Unit: KRW Million):
- Current Year: Total Assets 488,876 / Total Liabilities 33,038 / Total Equity 455,838
- Previous Year: Total Assets 479,815 / Total Liabilities 21,746 / Total Equity 458,068
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Regulatory Approval and Finalization of Expected Acquisition Date
This disclosure details Celltrion USA’s decision to acquire Imclone Systems LLC for approx. KRW 460.0B to secure US API manufacturing infrastructure, making it important to monitor the confirmation of the expected acquisition date upon obtaining necessary regulatory approvals. Tracking the transaction timeline and final closing ensures verification of the execution of US manufacturing plans. Final acquisition dates and closing progress can be verified through upcoming corrected disclosures or periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
